Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
Pharma Wakes Up To Transformative Progress In Hearing Loss Research
The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector.
Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down
While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.
Early Stage Candidates Carving Out New Routes In Cystic Fibrosis
Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.
Four Early-Stage Antibacterial Drugs To Watch: Highlights From IDWeek
Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.